Seminars in Hematology

Papers
(The TQCC of Seminars in Hematology is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Special issue on chronic lymphocytic leukemia: Prognostication and therapeutic options introductory editorial129
CAR T-cell therapy comes of age: Introductory editorial for the special issue57
Clinical applications of circulating tumor DNA in Hodgkin lymphoma38
Extramedullary myeloma in the era of CAR T-cell and bispecific antibody therapies31
Insights from the 12th International Workshop on Waldenstrom's Macroglobulinemia30
Clonality in immune aplastic anemia: Mechanisms of immune escape or malignant transformation28
Updates on current and future research in acute myeloid leukemia27
How to set up a clinical research center in Brazil, as an example of a middle-income country27
The winding road: Infectious disease considerations for CAR-T and other novel adoptive cellular therapies in the era of COVID-1921
Epidemiology and etiology of diffuse large B-cell lymphoma21
Lessons learned from the Eµ-TCL1 mouse model of CLL20
Somatic mutations in “benign” blood diseases18
Antibody and immunotherapy in diffuse large B-cell lymphoma17
The future of lymphoma diagnosis, prognosis, and treatment monitoring in countries with limited access to pathology services17
Immune-driven clonal cell selection at the intersection among cancer, infections, autoimmunity and senescence17
TET2 mutation as prototypic clonal hematopoiesis lesion17
The role of viruses in HIV-associated lymphomas15
More disease-modifying therapies for sickle cell disease: are small molecules and drug repurposing the way forward?15
MRD-driven treatment strategies in CLL: Current practice, limitations, and emerging paradigms15
Intestinal microbiome and myelodysplastic syndromes: Current state of knowledge and perspectives for future14
Report of Consensus Panel 5 from the 12th International Workshop on Waldenstrom's Macroglobulinemia on the management of patients with intolerance or resistance to covalent BTK inhibitors13
T-cell engaging antibodies for B-cell lymphomas13
The molecular map of CLL and Richter's syndrome13
Vaccinations in patients with chronic lymphocytic leukemia12
Roadmap for developing MRD as an early endpoint for drug approval in lymphoma12
Developing MRD as an early endpoint for accelerated approval in CLL12
At the cusp of a cure in Myeloma: Insights into pathogenesis, modeling and therapeutics11
Clonal hematopoiesis11
Accelerating accessibility of CAR-T/NK therapies – Are AlloCARs and rapid manufacturing platforms the road ahead in improving access in multiple myeloma?11
Cellular and immunotherapies for myelodysplastic syndromes11
outside front cover, PMS 8883 metallic AND 4/C11
B-cell receptor immunoglobulin stereotypy in chronic lymphocytic leukemia: Key to understanding disease biology and stratifying patients10
Role of MRD testing in acute myeloid leukemias. What is the status and how to get there?10
outside front cover, PMS 8883 metallic AND 4/C10
Challenges and opportunities of CAR T-cell therapies for CLL9
Report of Consensus Panel 3 from the 11th International workshop on Waldenström's Macroglobulinemia: Recommendations for molecular diagnosis in Waldenström's Macroglobulinemia9
Engineering the Next Generation of Antibody Therapeutics in Hematology9
Advancements in bispecific antibodies for multiple myeloma: What's new and what lies ahead9
Access to essential therapy for sickle cell disease in Africa: Experience from a national program in Ghana9
Management of Myelodysplastic Syndrome in Pregnant Patients: Treatment Approaches and Considerations9
The biology of classical Hodgkin lymphoma9
Mobilizing CARs: Benefits, drawbacks, and directions for outpatient CAR T-cell therapy9
A tower of babel of acronyms? The shadowlands of MGUS/MBL/CHIP/TCUS8
The pediatric approach to Hodgkin lymphoma8
Menin inhibition for the treatment of acute leukemia8
Harnessing single-domain antibodies for CAR-T and bispecific antibody development8
Report of Consensus Panel 2 from the 12th International Workshop on the management of Bing-Neel syndrome in patients with Waldenstrom’s Macroglobulinemia7
DLBCL arising from indolent lymphomas: How are they different?7
Somatic compensation of inherited bone marrow failure7
MRD as an early endpoint in myeloma and other hematologic malignancies: Implication for ongoing and future study designs7
The spectrum of somatic mutations in large granular lymphocyte leukemia, rheumatoid arthritis, and Felty's syndrome7
The emergence of a new paradigm with signal 1 and signal 2 T-cell engagers in hematology7
Report of consensus panel 7 from the 11th international workshop on Waldenström macroglobulinemia on priorities for novel clinical trials7
Somatic mutations in acquired pure red cell aplasia7
The crossroads of cancer therapies and clonal hematopoiesis7
Blood-based MRD testing in multiple myeloma: Update on mass spectrometry methods for detecting the monoclonal immunoglobulin7
Understanding MDS stem cells: Advances and limitations7
0.059137105941772